BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35559744)

  • 1. Pretreatment with a gonadotropin-releasing hormone agonist and an aromatase inhibitor may improve outcomes in in vitro fertilization cycles of women with stage I-II endometriosis.
    Piedimonte S; Volodarsky-Perel A; Tannus S; Tan SL; Dahan MH
    F S Sci; 2020 Aug; 1(1):98-103. PubMed ID: 35559744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of GnRH agonist and letrozole treatment in women with recurrent implantation failure.
    Steiner N; Shrem G; Tannus S; Dahan SY; Balayla J; Volodarsky-Perel A; Tan SL; Dahan MH
    Fertil Steril; 2019 Jul; 112(1):98-104. PubMed ID: 31133384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF.
    Cantor A; Tannus S; Son WY; Tan SL; Dahan MH
    Reprod Biomed Online; 2019 Apr; 38(4):520-527. PubMed ID: 30935663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis.
    Georgiou EX; Melo P; Baker PE; Sallam HN; Arici A; Garcia-Velasco JA; Abou-Setta AM; Becker C; Granne IE
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31747470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of recurrent implantation failure by gonadotropin-releasing hormone agonist and aromatase inhibitor suppression, in women without evidence of endometriosis.
    Khayat S; Elliott B; Dahan MH
    Gynecol Endocrinol; 2019 Mar; 35(3):267-270. PubMed ID: 30328740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
    Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis.
    Surrey ES; Silverberg KM; Surrey MW; Schoolcraft WB
    Fertil Steril; 2002 Oct; 78(4):699-704. PubMed ID: 12372443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
    Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
    Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultralong administration of gonadotropin-releasing hormone agonists before in vitro fertilization improves fertilization rate but not clinical pregnancy rate in women with mild endometriosis: a prospective, randomized, controlled trial.
    Kaponis A; Chatzopoulos G; Paschopoulos M; Georgiou I; Paraskevaidis V; Zikopoulos K; Tsiveriotis K; Taniguchi F; Adonakis G; Harada T
    Fertil Steril; 2020 Apr; 113(4):828-835. PubMed ID: 32147182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live birth rate comparison of three controlled ovarian stimulation protocols for in vitro fertilization-embryo transfer in patients with diminished ovarian reserve after endometrioma cystectomy: a retrospective study.
    Zhao F; Lan Y; Chen T; Xin Z; Liang Y; Li Y; Wang S; Zhang J; Yang X
    J Ovarian Res; 2020 Feb; 13(1):23. PubMed ID: 32113477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35-40 years.
    Tannus S; Turki R; Cohen Y; Son WY; Shavit T; Dahan MH
    Fertil Steril; 2017 Jun; 107(6):1323-1328.e2. PubMed ID: 28501366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy outcomes after controlled ovarian hyperstimulation in women with endometriosis-associated infertility: GnRH-agonist versus GnRH-antagonist.
    Kolanska K; Cohen J; Bendifallah S; Selleret L; Antoine JM; Chabbert-Buffet N; Darai E; d'Argent EM
    J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):681-686. PubMed ID: 28970135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.
    Meyer L; Murphy LA; Gumer A; Reichman DE; Rosenwaks Z; Cholst IN
    Fertil Steril; 2015 Sep; 104(3):637-42. PubMed ID: 26149355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.
    Giles J; Alama P; Gamiz P; Vidal C; Badia P; Pellicer A; Bosch E
    Fertil Steril; 2021 Aug; 116(2):404-412. PubMed ID: 33814126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.